利奈唑胺联合治疗非结核分枝杆菌肺病的近期疗效与安全性分析

Short-term efficacy and safety of linezolid combination treatment in non-tuberculosis mycobacterium tuberculosis

目的探究利奈唑胺联合治疗非结核分枝杆菌肺病的近期疗效与安全性,总结临床经验。方法将我院2015年8月至2016年6月收治的80例非结核分枝杆菌肺病患者分为对照组(行常规治疗)与观察组(行利奈唑胺联合常规治疗),各40例。观察两组患者的治疗有效性和安全性。结果观察组患者的治疗总有效率为77.5%,高于对照组患者的55.0%,差异具有统计学意义(P<0.05);两组患者的不良反应总发生率比较,差异不显著(P>0.05)。结论利奈唑胺联合治疗非结核分枝杆菌肺病的近期疗效较高,但临床使用时应密切观察患者情况。

Objective To explore the efficacy and safety of linezolid comb ination treatment in non -tuberculosismycobacterium tuberculosis. Methods Eighty cases of patients with non-tuberculous mycobacterium tuberculosis admittedin our hospital from August 2015 to June 2016 were divided into control group （treated with conventional treatment） andobservation group （treated with linezolid combined with conventional treatment）, with 40 cases in each group. The efficacyand safety of the two groups were observed. Results The total effective rate of the observation group was 77.5%, which washigher than 55.0% of the control group, the difference was statistically significant （P约0.05）. The difference in the totalincidences of adverse reactions between the two groups was not significant （P〉0.05）. Conclusion Linezolid combinationtreatment in non-tuberculosis mycobacterium tuberculosis has a high recent effect, but the situation of patients should beclosely observed in clinical using.